PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806
PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.